Repligen (NASDAQ:RGEN) Cut to “Sell” at StockNews.com

StockNews.com downgraded shares of Repligen (NASDAQ:RGEN) from a hold rating to a sell rating in a research note released on Friday.

Several other analysts have also recently commented on the company. Canaccord Genuity Group raised their target price on Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research report on Friday. TD Cowen initiated coverage on Repligen in a research note on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. Royal Bank of Canada lifted their target price on Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a research note on Friday. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Finally, Wolfe Research assumed coverage on shares of Repligen in a report on Thursday, November 14th. They set a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $181.00.

Repligen Stock Performance

Shares of NASDAQ RGEN opened at $158.99 on Friday. The stock’s fifty day simple moving average is $155.22 and its 200 day simple moving average is $148.59. The stock has a market capitalization of $8.91 billion, a price-to-earnings ratio of -311.75, a PEG ratio of 4.54 and a beta of 0.99. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen has a 52-week low of $113.50 and a 52-week high of $203.13.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. The firm had revenue of $167.55 million for the quarter, compared to analysts’ expectations of $167.58 million. As a group, sell-side analysts forecast that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of RGEN. Champlain Investment Partners LLC lifted its position in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Repligen by 11.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock valued at $1,027,165,000 after acquiring an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Repligen by 183.1% in the 4th quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after acquiring an additional 594,189 shares in the last quarter. Groupama Asset Managment lifted its holdings in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock worth $58,142,000 after purchasing an additional 400,680 shares during the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in Repligen during the fourth quarter worth approximately $53,428,000. Institutional investors own 97.64% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.